Login to Your Account

Financings NEWS
Just six months after completing an upsized $203.6 million follow-on offering in January, Alder Biopharmaceuticals Inc. is seeking an additional $200 million in a new offering of about 4.5 million shares (NASDAQ:ALDR) to back development and testing of ALD403, a calcitonin gene-related peptide blocker it's developing for migraine prevention.
Clementia Pharmaceuticals Inc. completed a $60 million mezzanine financing round to support continued development of its lead compound, palovarotene (formerly Clm-001), to treat fibrodysplasia ossificans progressiva (FOP).

PHILADELPHIA – Anything an antibody can do, only better: That's the big idea behind Cytomx Inc.'s Probody platform.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: